CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl

In this series of videos, three lipids experts discuss the following topics: residual CV risk, findings of CV outcome trials with icosapent ethyl and potential mechanism of benefit with icosapent ethyl.

Episodes 1-3 of 3

  • Potential mechanisms of benefit of icosapent ethylPotential mechanisms of benefit of icosapent ethyl
    CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl
    Potential mechanisms of benefit of icosapent ethyl
    • Prof. Chris Packard, PhD
      Prof. Chris Packard, PhD

      Prof. Chris Packard, PhD

  • Exploring the role of icosapent ethyl based on current clinical evidenceExploring the role of icosapent ethyl based on current clinical evidence
    CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl
    Exploring the role of icosapent ethyl based on current clinical evidence
    • Prof. Wouter Jukema, MD, PhD
      Prof. Wouter Jukema, MD, PhD

      Prof. Wouter Jukema, MD, PhD

  • Residual CV risk in patients on statin therapyResidual CV risk in patients on statin therapy
    CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl
    Residual CV risk in patients on statin therapy
    • Prof. Alberto Zambon, MD, PhD
      Prof. Alberto Zambon, MD, PhD

      Prof. Alberto Zambon, MD, PhD

Register

We're glad to see you're enjoying PACE-CME…
but how about a more personalized experience?

Register for free